Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019064304) METHODS AND COMPOSITIONS FOR TREATING MULTIPLE SCLEROSIS
Latest bibliographic data on file with the International BureauSubmit observation

Pub. No.: WO/2019/064304 International Application No.: PCT/IL2018/051072
Publication Date: 04.04.2019 International Filing Date: 27.09.2018
IPC:
A61K 39/395 (2006.01) ,A61P 25/00 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
395
Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25
Drugs for disorders of the nervous system
Applicants:
YAYON, Avner [IL/IL]; IL
ROM, Eran [IL/IL]; IL
Inventors:
YAYON, Avner; IL
ROM, Eran; IL
Agent:
WEBB, Cynthia; IL
BARZAM, Maty; IL
BOGIN, Liora; IL
BURSTEIN, Tal; IL
FINAROV, Igal; IL
GANOR, Sharon; IL
HORNIK, Vered; IL
NOAH, Eran; IL
POTASH, Shay; IL
SCHICKLER, Hedva; IL
SCHVARTZ, Iris; IL
SILVERMAN, Eran; IL
TRAVITSKY, Nina; IL
WEBB, Yael; IL
ZIPOR, Gadi; IL
Priority Data:
62/564,27728.09.2017US
Title (EN) METHODS AND COMPOSITIONS FOR TREATING MULTIPLE SCLEROSIS
(FR) MÉTHODES ET COMPOSITIONS POUR LE TRAITEMENT DE LA SCLÉROSE EN PLAQUES
Abstract:
(EN) The present invention relates to compositions and methods of treating multiple sclerosis. Particularly, the present invention relates to pharmaceutical compositions comprising antibodies having affinity to both fibroblast growth factor receptor 2 (FGFR2) and FGFR3 for use in treating multiple sclerosis.
(FR) La présente invention concerne des compositions et des méthodes de traitement de la sclérose en plaques. En particulier, la présente invention concerne des compositions pharmaceutiques comprenant des anticorps ayant une affinité vis-à-vis du récepteur 2 du facteur de croissance des fibroblastes (FGFR2) et du FGFR3 pour une utilisation dans le traitement de la sclérose en plaques.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)